Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma

• Published in: JNCI : Journal of the National Cancer Institute 2019-11, Vol.111 (11), p.1192-1201
• Main Authors: Oldridge, Derek A, Truong, Bao, Russ, Douglas, DuBois, Steven G, Vaksman, Zalman, Mosse, Yael P, Diskin, Sharon J, Maris, John M, Matthay, Katherine K
• Format: Article
• Language: English
• Subjects: Adrenal glands; Amplification; Biology; Chromosome 1; Chromosome 11; Chromosome deletion; Chromosomes; Confidence intervals; Deoxyribonucleic acid; Developmental biology; Diagnostic systems; DNA; Gain; Ganglia; Health risks; Lung cancer; Mutation; Nervous system; Neuroblastoma; Nucleotides; Ribonucleic acid; RNA; Single-nucleotide polymorphism; Sympathetic ganglia; Sympathetic nervous system; Tumors
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djz027

Abstract Background Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system. Methods We first compared genomic and epigenomic data of primary diagnostic neuroblastomas originating in the adrenal gland (n = 646) compared to thoracic sympathetic ganglia (n = 118). We also evaluated association of common germline variation with these primary sites in 1027 European-American neuroblastoma patients. Results We observed higher rates of MYCN amplification, chromosome 1q gain, and chromosome 11q deletion among adrenal tumors, which were highly predictive of functional RNA signatures. Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio = 1.89, 95% confidence interval = 1.04 to 3.43), and among cases without MYCN amplification (odds ratio = 2.86, 95% confidence interval = 1.48 to 5.49). Common germline single nucleotide polymorphisms (SNPs) in BARD1 (previously associated with high-risk neuroblastoma) were found to be strongly associated with predisposition for origin at adrenal, rather than thoracic, sites. Conclusions Neuroblastomas arising in the adrenal gland are more likely to harbor structural DNA aberrations including MYCN amplification, whereas thoracic tumors show defects in mitotic checkpoints resulting in hyperdiploidy. Despite the general association of ALK mutations with high-risk disease, thoracic tumors are more likely to harbor gain-of-function ALK aberrations. Site of origin is likely reflective of stage of sympathetic nervous system development when malignant transformation occurs and is a surrogate for underlying tumor biology.